$202 Million is the total value of Sio Capital Management, LLC's 44 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -38,312 | -100.0% | -0.01% | – |
| Exit | HUMACYTE INC*w exp 08/27/202 | $0 | – | -49,998 | -100.0% | -0.01% | – | |
| ASLN | Exit | ASLAN PHARMACEUTICALS LTDads | $0 | – | -1,270,758 | -100.0% | -0.17% | – |
| SIEN | Exit | SIENTRA INC | $0 | – | -2,550,000 | -100.0% | -0.19% | – |
| CNTB | Exit | CONNECT BIOPHARMA HOLDINGS LTDads | $0 | – | -597,678 | -100.0% | -0.19% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INCput | $0 | – | -235,600 | -100.0% | -0.30% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -235,500 | -100.0% | -0.30% | – |
| Exit | TYRA BIOSCIENCES INC | $0 | – | -152,159 | -100.0% | -0.43% | – | |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -1,825,963 | -100.0% | -0.67% | – |
| ISEE | Exit | IVERIC BIO INCput | $0 | – | -86,400 | -100.0% | -0.68% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQUISITIONS CORP 2 | $0 | – | -250,000 | -100.0% | -0.92% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCput | $0 | – | -67,000 | -100.0% | -0.94% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -555,610 | -100.0% | -1.29% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -340,000 | -100.0% | -1.29% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -434,635 | -100.0% | -1.75% | – |
| ICLR | Exit | ICON PLC | $0 | – | -33,983 | -100.0% | -2.44% | – |
| STAA | Exit | STAAR SURGICAL CO | $0 | – | -157,129 | -100.0% | -2.82% | – |
| DGX | Exit | QUEST DIAGNOSTICS INCput | $0 | – | -92,000 | -100.0% | -5.32% | – |
| MSAC | Exit | MEDICUS SCIENCES ACQUISITION | $0 | – | -2,323,000 | -100.0% | -8.65% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INCput | $0 | – | -574,200 | -100.0% | -23.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.